Following Immix’s update at the 61st annual American Society of Clinical Oncology conference (ASCO 2025), the company hosted a key opinion leader (KOL) event, which showcased the potential of NXC-201 as an effective treatment option to address the unmet need for patients with relapsed/refractory am

06 Jun 2025
Immix Biopharma:ASCO/KOL event reaffirms NXC-201’s potential

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Immix Biopharma:ASCO/KOL event reaffirms NXC-201’s potential
Immix Biopharma, Inc. (IMMX:NAS) | 0 0 0.0%
- Published:
06 Jun 2025 -
Author:
Jyoti Prakash, CFA | Arron Aatkar, PhD -
Pages:
2 -
Following Immix’s update at the 61st annual American Society of Clinical Oncology conference (ASCO 2025), the company hosted a key opinion leader (KOL) event, which showcased the potential of NXC-201 as an effective treatment option to address the unmet need for patients with relapsed/refractory am